Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385689 | 1.00 | CHRM2 (0.32) | CHRM2CHRM1CHRM3ESR1SCN9A | |
| SCHEMBL6840077 | 1.00 | CHRM2 (0.32) | CHRM2CHRM1CHRM3ESR1SCN9A | |
| SCHEMBL2744760 | 0.84 | KDM4E (0.33) | CHRM2CHRM1CHRM3ESR1 | |
| SCHEMBL2744763 | 0.84 | KDM4E (0.33) | CHRM2CHRM1CHRM3ESR1 | |
| SCHEMBL6838110 | 0.81 | CHRM2 (0.57) | CHRM2CHRM1CHRM3 | |
| SCHEMBL907262 | 0.81 | CHRM2 (0.57) | CHRM2CHRM1CHRM3 | |
| SCHEMBL16114797 | 0.80 | HCRTR2 (0.35) | — | |
| SCHEMBL23387608 | 0.78 | ACHE (0.34) | ESR1 | |
| SCHEMBL22236438 | 0.78 | ACHE (0.34) | ESR1 | |
| SCHEMBL23387609 | 0.78 | ACHE (0.34) | ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-8658654-B2 | Receptor-type kinase modulators and methods of use | SYMPHONY EVOLUTION, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2277867-B1 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | SYMPHONY EVOLUTION INC (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | CHRM2 1646/4885CHRM1 666/4885CHRM3 1650/4885 |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | CHRM2 4039/4885CHRM1 4008/4885CHRM3 3403/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | CHRM2 2871/4885CHRM1 2536/4885CHRM3 2540/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | CHRM2 4039/4885CHRM1 4008/4885CHRM3 3403/4885 |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | CHRM2 4039/4885CHRM1 4008/4885CHRM3 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.